Skip to main content
  • Home
  • Articles
    • Archive from 2022 July
    • Archive 1960 to 2022 June
    • Accepted Articles
    • Published Ahead-of-Print
    • Supplement
  • About
  • For Authors
  • Podcasts

Prolonged pruritic rash following influenza A (H1N1) vaccination

< Back to Listing

Share this Article

Singapore Med J2013; 54(5): e117-e119; http://dx.doi.org/10.11622/smedj.2013094
Prolonged pruritic rash following influenza A (H1N1) vaccination

  • Abstract
  • PDF
  • References

Qin Y, Thomas CK
Correspondence: Dr Qin Yan, qin_yan@yahoo.com

ABSTRACT
In Singapore, the approved influenza A (H1N1) vaccines are Panvax® and Pandemrix®. An estimated 425,000 doses of Panvax and less than 100 doses of Pandemrix had been distributed in Singapore from November 2009 to February 2010. Reviews on the H1N1 vaccine have concluded that it has a safety profile similar to that of seasonal influenza vaccines. From the time the H1N1 vaccination was implemented in Singapore on November 3, 2009, up to October 11, 2010, the Health Sciences Authority had received 173 adverse event reports from healthcare professionals. We report a case of prolonged illness after H1N1 vaccination.

Keywords: adverse effect, H1N1 vaccine
Singapore Med J2013; 54(5): e117-e119; http://dx.doi.org/10.11622/smedj.2013094

http://smj.org.sg/sites/default/files/5405/5405cr7.pdf

REFERENCES

1. World Health Organization. DG Statement following the meeting of the Emergency Committee. In: World Health Organization: Global Alert and Response (GAR) [online]. Available at: www.who.int/csr/disease/swineflu/4th_meeting_ihr/en/index.html. Accessed October 10, 2010.
 
2. Kuehn BM. CDC names H1N1 vaccine priority groups. JAMA 2009; 302:1157-8.
http://dx.doi.org/10.1001/jama.2009.1312
 
3. Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009; 361:2405-13.
http://dx.doi.org/10.1056/NEJMoa0907413
 
4. Health Sciences Authority, Singapore. Update on safety monitoring of H1N1 vaccines from 3 November 2009 to 28 February 2010 [online]. Available at: www.hpp.moh.gov.sg. Accessed October 11, 2010.
 
5. Black, S, Eskola, J, Siegrist, CA, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009; 374:2115-22.
http://dx.doi.org/10.1016/S0140-6736(09)61877-8
 
6. Centres for Disease Control and Prevention (CDC). Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:1351-6.
 
7. Liang XF, Li L, Liu DW, et al. Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China. N Engl J Med 2011; 364:638-47.
http://dx.doi.org/10.1056/NEJMoa1008553
 
8. Talbot HK, Keitel W, Cate TR, et al. Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine 2008; 26:4057-61.
http://dx.doi.org/10.1016/j.vaccine.2008.05.024
 
9. CSL Limited. Panvax® Product Information. Available at: http://www.peelregion.ca/health/professionals/pdfs/panvax-vaccine.pdf.
×

Around the Site

Home

About SMJ

For Reviewers

Sign Up for Alerts

Issues

Current Issue

All Issues

Online First

Supplement

CME

For Authors

Instructions for Authors

Submit Manuscript


Follow us on:
        

More Links

Contact Us

Copyright

Advertise

SMJ Forms

Privacy Policy

SMA Home

Copyright 2021. Singapore Medical Association. All Rights Reserved.